Clearmind Medicine (CMND) announced the filing of an Israeli patent application for its combination therapy of 5-methoxy-2-aminoindane and N-Acylethanolamines, such as Palmitoylethanolamide, addressing depression. The patent application stems from Clearmind’s collaboration with Neurothera Labs, a subsidiary of SciSparc (SPRC). This therapy targets depression treatment using the combination of MEAI and PEA. According to the World Health Organization, major depressive disorder affects more than 280M people worldwide and remains one of the leading causes of disability, with limited innovative treatment options available.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- Psychedelic: Atai Beckley, Cybin report quarterly earnings
- Clearmind Medicine receives final approval to expand Phase 1/2a AUD trial
- Clearmind announces notice of publication of patent for MEAI in China
- Clearmind Medicine completes first cohort treatment in Phase I/IIa AUD trial
- Psychedelic: Compass Pathways, GH Research report Q3 earnings